+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

IBD - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 4851974
  • Report
  • November 2019
  • Region: Global
  • 195 pages
  • Transparency Market Research
1 of 3

FEATURED COMPANIES

  • AbbVie, Inc.
  • Allergan plc.
  • Biogen Inc.
  • Novartis AG
  • Pfizer, Inc.
  • UCB Inc.
  • MORE
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market - Scope of the Report

The report on the global IBD (ulcerative colitis and Crohn’s disease) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global IBD (ulcerative colitis and Crohn’s disease) treatment market for the period of 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global IBD treatment market for the forecast period.

The report has been prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global IBD (ulcerative colitis and Crohn’s disease) treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global IBD (ulcerative colitis and Crohn’s disease) treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global IBD treatment market. The next section of the global IBD (ulcerative colitis and Crohn’s disease) treatment report highlights the USPs, which include disease prevalence: IBD (ulcerative colitis and Crohn’s disease) globally, IBD (ulcerative colitis and Crohn’s disease) treatment pipeline analysis, and major deals and strategic alliances analysis in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.

The report delves into the competitive landscape of the global IBD (ulcerative colitis and Crohn’s disease) treatment market. Key players operating in the global IBD treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overviews, financial standings, recent developments, and SWOT are some of the attributes of the players profiled in the global IBD (ulcerative colitis and Crohn’s disease) treatment market report.

Key Questions Answered in Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Report
  • What is the sales/revenue expected to be generated by IBD (ulcerative colitis and Crohn’s disease) treatment products across all the regions during the forecast period?
  • What are the key trends in the IBD (ulcerative colitis and Crohn’s disease) treatment market?
  • What are the major drivers, restraints, and opportunities in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment will have the highest revenue, globally, in 2027, and which product segment will expand at the fastest CAGR during the forecast period?
Global IBD Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global IBD (ulcerative colitis and Crohn’s disease) treatment market begins with an overview of the said market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of this study and healthcare compliances laid down by accredited agencies in the purview of research in the global IBD (ulcerative colitis and Crohn’s disease) treatment market. It is followed by a market introduction, market dynamics, and an overview of the global IBD treatment market, which includes an’s analysis of the market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights have been provided to understand the Y-o-Y trends of the IBD (ulcerative colitis and Crohn’s disease) treatment market. The next section of the global IBD (ulcerative colitis and Crohn’s disease) treatment report highlights the USPs, including disease prevalence, globally, treatment pipeline analysis, and major deals & strategic alliance analysis in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of the key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key IBD (ulcerative colitis and Crohn’s disease) treatment players has been mapped to ascertain the size of the global IBD (ulcerative colitis and Crohn’s disease) treatment market in terms of value. The forecasts presented here assess the total revenue generated in the IBD (ulcerative colitis and Crohn’s disease) treatment market. In order to provide an accurate forecast, we initiated by sizing up the current IBD (ulcerative colitis and Crohn’s disease) treatment market with the help of the parent market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie, Inc.
  • Allergan plc.
  • Biogen Inc.
  • Novartis AG
  • Pfizer, Inc.
  • UCB Inc.
  • MORE
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market

4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, 2017–2027

5. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market, Key Insights
5.1. Clinical Trial Pipeline Analysis: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market
5.2. Disease Prevalence: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market
5.3. Major Deals & Strategic Alliances Analysis: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

6. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
6.3.1. TNF Inhibitors
6.3.2. Aminosalicylates
6.3.3. Integrin Antagonists
6.3.4. Corticosteroids
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class

7. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Disease Indication
7.1. Key Findings
7.2. Introduction
7.3. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
7.3.1. Ulcerative Colitis
7.3.2. Crohn’s Disease
7.4. Market Attractiveness Analysis, by Disease Indication

8. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Value (US$ Mn) Forecast by Distribution Channel, 2019–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2019–2027
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region

10. North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
10.1. Key Findings
10.2. Market Value (US$ Mn) Forecast, by Country, 2019–2027
10.2.1. U.S.
10.2.2. Canada
10.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
10.3.1. TNF Inhibitors
10.3.2. Aminosalicylates
10.3.3. Integrin Antagonists
10.3.4. Corticosteroids
10.3.5. Others
10.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
10.4.1. Ulcerative Colitis
10.4.2. Crohn’s Disease
10.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Drug Class
10.6.3. By Disease Indication
10.6.4. By Distribution Channel

11. Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
11.1. Key Findings
11.2. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
11.3.1. TNF Inhibitors
11.3.2. Aminosalicylates
11.3.3. Integrin Antagonists
11.3.4. Corticosteroids
11.3.5. Others
11.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
11.4.1. Ulcerative Colitis
11.4.2. Crohn’s Disease
11.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Attractiveness Analysis
11.6.1. By Country/Sub-region
11.6.2. By Drug Class
11.6.3. By Disease Indication
11.6.4. By Distribution Channel

12. Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
12.4.1. TNF Inhibitors
12.4.2. Aminosalicylates
12.4.3. Integrin Antagonists
12.4.4. Corticosteroids
12.4.5. Others
12.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
12.5.1. Ulcerative Colitis
12.5.2. Crohn’s Disease
12.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Attractiveness Analysis
12.7.1. By Country/Sub-region
12.7.2. By Drug Class
12.7.3. By Disease Indication
12.7.4. By Distribution Channel

13. Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
13.4.1. TNF Inhibitors
13.4.2. Aminosalicylates
13.4.3. Integrin Antagonists
13.4.4. Corticosteroids
13.4.5. Others
13.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
13.5.1. Ulcerative Colitis
13.5.2. Crohn’s Disease
13.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Attractiveness Analysis
13.7.1. By Country/Sub-region
13.7.2. By Drug Class
13.7.3. By Disease Indication
13.7.4. By Distribution Channel

14. Middle East and Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East and Africa
14.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
14.4.1. TNF Inhibitors
14.4.2. Aminosalicylates
14.4.3. Integrin Antagonists
14.4.4. Corticosteroids
14.4.5. Others
14.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
14.5.1. Ulcerative Colitis
14.5.2. Crohn’s Disease
14.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Attractiveness Analysis
14.7.1. By Country/Sub-region
14.7.2. By Drug Class
14.7.3. By Disease Indication
14.7.4. By Distribution Channel

15. Competition Landscape
15.1. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Share, by Company, 2018
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. Janssen Biotech, Inc. (Johnson & Johnson)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Valeant Pharmaceuticals International, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Allergan plc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Takeda Pharmaceutical Company Limited.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. AbbVie, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Novartis AG
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. UCB Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Biogen Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer, Inc.
  • Janssen Biotech, Inc. (Johnson & Johnson)
  • Valeant Pharmaceuticals International, Inc.
  • Allergan plc.
  • Takeda Pharmaceutical Company Limited.
  • AbbVie, Inc.
  • Novartis AG
  • UCB Inc.
  • Biogen Inc.
Note: Product cover images may vary from those shown
Adroll
adroll